Naltrexone and Disulfiram in Patients With Alcohol Dependence and Current Depression
The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Although disulfiram and naltrexone have been approved by the Food and Drug Administration for the treatment of alcoholism, no medications have been approved for individuals with alcohol dependence and comorbid psychiatric disorders. In particular, the effect of these medications on alcohol use outcomes and on specific psychiatric symptoms is still unknown in patients with the most common co-occurring disorder, major depression. METHOD: Two hundred fifty-four patients with a major Axis I psychiatric disorder and comorbid alcohol dependence were treated for 12 weeks in an outpatient medication study conducted at 3 Veterans Administration outpatient clinics. Randomization included (1) open randomization to disulfiram or no disulfiram, and (2) double-blind randomization to naltrexone or placebo. This resulted in 4 groups: (1) naltrexone alone, (2) placebo alone, (3) disulfiram and naltrexone, and (4) disulfiram and placebo. Primary outcomes were measures of alcohol use. Secondary outcomes included psychiatric symptoms assessed by the Hamilton Depression Rating Scale, alcohol craving, gamma-glutamyltransferase levels, and adverse events. RESULTS: One hundred thirty-nine subjects (54.7%) met the current Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria for major depression. There was no relationship between the diagnosis of depression and medication treatment on alcohol use outcomes, psychiatric symptoms, or the reporting of side effects for these medications. There was a significant interaction between diagnosis, medication group, and craving, where subjects with depression on disulfram reported lower craving over time than subjects with depression on naltrexone. CONCLUSIONS: The results suggest that disulfiram and naltrexone are safe pharmacotherapeutic agents for dually diagnosed individuals with depression for the treatment of alcohol use disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Agents for primary alcohol use disorder may also show benefits in BD, such as disulfiram (level 3),688, 689, 690, 691 naltrexone (level 3)692, 693, 694, 695 and gabapentin (level 4).696, 697”
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
The Hopkins Symptom Checklist (HSCL): A self-report symptom inventory
Derogatis, L. R., Lipman, R. S., Rickels, K., Uhlenhuth, E. H., & Covi, L. (1974) · Behavioral Science · doi:10.1002/bs.3830190102 · Cited by 4,604
The Structured Clinical Interview for DSM-III-R (SCID): I: History, Rationale, and Description
Spitzer, R. L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820080032005 · Cited by 4,336
Regier, D. A. (1990) · JAMA · doi:10.1001/jama.1990.03450190043026 · Cited by 3,962 · cited 7×
“This resulted in the following groups: (1) naltrexone alone, (2) placebo alone, (3) disulfiram and naltrexone, and (4) disulfiram and placebo.”
BackgroundMethodInfluentialThe Neural Basis of Addiction: A Pathology of Motivation and Choice
Kalivas, P. W., & Volkow, N. D. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.8.1403 · Cited by 2,757
Treatment of Depression in Patients With Alcohol or Other Drug Dependence: A Meta-analysis
Nunes, E. V., & Levin, F. R. (2004) · JAMA · doi:10.1001/jama.291.15.1887 · Cited by 532
Anton, R. F. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830030047008 · Cited by 511
Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram
Carroll, K. M., Nich, C., Ball, S. A., Mccance, E., & Rounsavile, B. J. (1998) · Addiction · doi:10.1046/j.1360-0443.1998.9357137.x · Cited by 375
Self-citationCroop, R. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830240090013 · Cited by 211 · cited 2×
“This resulted in the following groups: (1) naltrexone alone, (2) placebo alone, (3) disulfiram and naltrexone, and (4) disulfiram and placebo.”
BackgroundMethodNaltrexone for alcohol dependence: a randomized controlled trial
Morris, P. L. P., Hopwood, M., Whelan, G., Gardiner, J., & Drummond, E. (2001) · Addiction · doi:10.1046/j.1360-0443.2001.961115654.x · Cited by 200
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Alcohol use disorder and depressive disorders
McHugh, R. (2019) · Alcohol Research: Current Reviews · doi:10.35946/arcr.v40.1.01 · Cited by 517
Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis
McPheeters, M., O’Connor, E. A., Riley, S., Kennedy, S. M., Voisin, C., Kuznacic, K., Coffey, C. P., Edlund, M. D., Bobashev, G., & Jonas, D. E. (2023) · JAMA · doi:10.1001/jama.2023.19761 · Cited by 285
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
Treatment of substance abusing patients with comorbid psychiatric disorders
Kelly, T. M., Daley, D. C., & Douaihy, A. B. (2012) · Addictive Behaviors · doi:10.1016/j.addbeh.2011.09.010 · Cited by 284
Metadata
- Authors
- Petrakis, I., Ralevski, E., Nich, C., Levinson, C., Carroll, K., Poling, J., & Rounsaville, B.
- Affiliations
- Yale University (US)
- Corresponding author
- Petrakis, Ismene
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2007-04
- Volume
- 27
- Issue
- 2
- Pages
- 160-165
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2066906665
- Cited by
- 66
- References
- 26
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 1 · 2023: 1 · 2022: 3 · 2021: 1 · 2020: 3 · 2019: 3 · 2018: 6 · 2017: 4 · 2016: 6 · 2015: 2 · 2014: 4 · 2013: 1 · 2012: 7
- FWCI
- 3.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- naltrexone, disulfiram, alcoholism, major depressive disorder, psychiatric comorbidity, alcohol craving, alcohol use outcomes, veterans, pharmacotherapy, gamma-glutamyl transferase, adverse events
- MeSH terms
- Alcohol Deterrents, Alcoholism, Bipolar Disorder, Connecticut, Major Depressive Disorder, Disulfiram, Double-Blind Method, Drug Therapy, Combination, Female, gamma-Glutamyltransferase, Gastrointestinal Diseases, Humans, Male, Massachusetts, Middle Aged, Naltrexone, Narcotic Antagonists, Psychiatric Status Rating Scales, Psychotic Disorders, Schizophrenia, Stress Disorders, Post-Traumatic, Veterans, Comorbidity, Treatment Outcome, Cocaine-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Naltrexone and Disulfiram in Patients With Alcohol Dependence and Current Depression. https://app.cochat.ai/papers/10.1097/jcp.0b13e3180337fcb
- The paper
- Petrakis, I., Ralevski, E., Nich, C., Levinson, C., Carroll, K., Poling, J., & Rounsaville, B. (2007). Naltrexone and Disulfiram in Patients With Alcohol Dependence and Current Depression. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b13e3180337fcb
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.